Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:INDP NASDAQ:LIAN NASDAQ:ONCT NASDAQ:PRTG On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeINDPIndaptus Therapeutics$7.30-10.5%$10.36$7.30▼$59.36$4.67M1.1424,014 shs9,424 shsLIANLianBio$0.05$0.30$0.27▼$4.99$5.87M0.231.04 million shs3 shsONCTOncternal Therapeutics$0.53$0.53$0.53▼$7.17$1.56M1.1899,758 shsN/APRTGPortage Biotech$5.42-9.1%$6.38$2.10▼$23.01$6.25M0.2418,712 shs20,512 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceINDPIndaptus Therapeutics-10.54%-26.41%-34.76%-43.32%-87.22%LIANLianBio0.00%+8.92%-87.26%-73.75%-82.76%ONCTOncternal Therapeutics0.00%0.00%0.00%0.00%-91.90%PRTGPortage Biotech-9.06%-5.41%-7.19%-47.22%+53.89%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationINDPIndaptus Therapeutics2.9087 of 5 stars3.55.00.00.00.01.71.3LIANLianBioN/AN/AN/AN/AN/AN/AN/AN/AONCTOncternal Therapeutics1.5459 of 5 stars3.10.00.00.00.60.81.3PRTGPortage BiotechN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceINDPIndaptus Therapeutics 3.00Buy$238.003,160.27% UpsideLIANLianBio 0.00N/AN/AN/AONCTOncternal Therapeutics 2.25Hold$10.001,798.97% UpsidePRTGPortage Biotech 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookINDPIndaptus TherapeuticsN/AN/AN/AN/A$10.84 per shareN/ALIANLianBioN/AN/AN/AN/A$2.71 per shareN/AONCTOncternal Therapeutics$790K1.97N/AN/A$10.19 per share0.05PRTGPortage BiotechN/AN/AN/AN/A$3.74 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateINDPIndaptus Therapeutics-$15.02M-$41.74N/AN/AN/AN/A-333.02%-216.36%8/11/2025 (Estimated)LIANLianBio-$110.29M-$0.81N/AN/AN/AN/A-33.17%-30.19%N/AONCTOncternal Therapeutics-$39.48M-$11.69N/AN/AN/A-1,599.95%-177.58%-131.30%N/APRTGPortage Biotech-$6.77M-$41.65N/A∞N/AN/AN/AN/A8/26/2025 (Estimated)Latest ONCT, INDP, PRTG, and LIAN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2025N/AINDPIndaptus Therapeutics-$0.36N/AN/AN/AN/AN/A5/14/2025Q1 2025INDPIndaptus Therapeutics-$11.48-$8.96+$2.52-$0.32N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthINDPIndaptus TherapeuticsN/AN/AN/AN/AN/ALIANLianBioN/AN/AN/AN/AN/AONCTOncternal TherapeuticsN/AN/AN/AN/AN/APRTGPortage BiotechN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioINDPIndaptus TherapeuticsN/A1.901.90LIANLianBioN/A10.0610.06ONCTOncternal TherapeuticsN/A2.392.39PRTGPortage BiotechN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipINDPIndaptus Therapeutics7.06%LIANLianBio74.85%ONCTOncternal Therapeutics16.05%PRTGPortage Biotech13.36%Insider OwnershipCompanyInsider OwnershipINDPIndaptus Therapeutics20.80%LIANLianBio7.59%ONCTOncternal Therapeutics11.20%PRTGPortage Biotech42.07%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableINDPIndaptus Therapeutics6570,000454,000Not OptionableLIANLianBio110108.06 million99.86 millionNot OptionableONCTOncternal Therapeutics302.96 million2.63 millionNo DataPRTGPortage Biotech61.05 million608,000OptionableONCT, INDP, PRTG, and LIAN HeadlinesRecent News About These CompaniesPortage Biotech Reports Results for Fiscal Year Ended March 31, 2025July 25, 2025 | globenewswire.comPortage Biotech Regains Nasdaq Compliance, Maintains Listing On Capital Market | NasdaqJune 27, 2025 | nasdaq.comPRTG Portage Biotech Inc. - Seeking AlphaJune 26, 2025 | seekingalpha.comPortage Biotech Inc. (PRTG) Income Statement - Yahoo FinanceJune 26, 2025 | finance.yahoo.comPortage Biotech Regains Nasdaq ComplianceJune 25, 2025 | tipranks.comPortage Biotech Regains Full Compliance with Nasdaq Continued Listing RequirementsJune 25, 2025 | globenewswire.comPortage Biotech Inc. (PRTG) Cash Flow - Yahoo FinanceJune 24, 2025 | finance.yahoo.comPortage Biotech acquires stake in Compedica for $5 millionJune 10, 2025 | investing.comPortage Biotech and Compedica Forge Strategic Alliance with Stock ExchangeJune 9, 2025 | tipranks.comPortage Biotech Inc. Enters Subscription Agreement with Compedica Holdings Limited for Strategic Equity InvestmentJune 9, 2025 | quiverquant.comQPortage Biotech and Compedica Stock-for-Stock ExchangeJune 9, 2025 | globenewswire.comPortage Biotech Shares Rise on Confirmatory Trial Results, Plans for Human TrialApril 28, 2025 | marketwatch.comPortage Biotech stock soars on promising preclinical resultsApril 28, 2025 | za.investing.comPortage Biotech Stock Surges On New Preclinical Data In Mesothelioma Trial: Retail Gets More BullishApril 28, 2025 | msn.comPortage Biotech Inc. Reports Positive Preclinical Efficacy Data for PORT-7 at AACR Annual Meeting 2025April 28, 2025 | quiverquant.comQPortage Biotech Reports Confirmatory Preclinical Results in Mesothelioma Supporting First-In-Human Trial of PORT-7April 28, 2025 | globenewswire.comInsider Stock Buying Reaches US$2.15m On Portage BiotechApril 26, 2025 | finance.yahoo.comPortage Biotech Inc. Common Stock (PRTG) Pre-MarketMarch 30, 2025 | nasdaq.comPortage Biotech presents preclinical data for PORT-7March 28, 2025 | markets.businessinsider.comPortage Biotech Shares More Than Double After Results of PORT-7 Tumor Treatment TrialMarch 27, 2025 | marketwatch.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeONCT, INDP, PRTG, and LIAN Company DescriptionsIndaptus Therapeutics NASDAQ:INDP$7.30 -0.86 (-10.54%) Closing price 08/1/2025 03:59 PM EasternExtended Trading$7.40 +0.09 (+1.30%) As of 08/1/2025 06:14 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York.LianBio NASDAQ:LIAN$0.05 0.00 (0.00%) As of 08/1/2025LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis and meibomian gland disease; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of second-line and first-line cholangiocarcinoma, and gastric cancers; BBP-398 for solid tumors; Omilancor and NX-13 for ulcerative colitis and Crohn's disease; LYR-210 for chronic rhinosinusitis; and Sisunatovir for respiratory syncytical virus. It has a partnership with Tarsus Pharmaceuticals, Inc. to develop and commercialize TP-03 for the treatment of Demodex blepharitis; and Nanobiotix S.A. to develop and commercialize NBTXR3, a radioenhancer designed to be injected directly into a malignant tumor prior to standard radiotherapy. The company was incorporated in 2019 and is headquartered in Princeton, New Jersey.Oncternal Therapeutics NASDAQ:ONCTOncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial. It is also developing ONCT-808, a chimeric antigen receptor T-cells (CAR-T), which is in Phase 1/2 clinical trial for the treatment of hematologic malignancies and solid tumors, as well as targets ROR1; and ONCT-534, a dual-action androgen receptor inhibitor product candidate in preclinical development for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. The company has license agreements with the Regents of the University of California; Georgetown University; The University of Texas MD Anderson Cancer Center; Shanghai Pharmaceutical (USA) Inc.; and University of Tennessee Research Foundation. Oncternal Therapeutics, Inc. is headquartered in San Diego, California.Portage Biotech NASDAQ:PRTG$5.42 -0.54 (-9.06%) Closing price 08/1/2025 03:59 PM EasternExtended Trading$5.44 +0.01 (+0.28%) As of 08/1/2025 07:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Portage Biotech Inc., a clinical stage immune-oncology company, engages in the research and develops pharmaceutical and biotechnology products. Its product pipeline includes PORT-2 for treatment of refractory NSCLC, melanoma, and refractory melanoma that is in phase I and phase II clinical trials; PORT-3, for treatment of solid tumors, which is in phase I clinical trials; PORT-6, an A2AR inhibitor to treat A2A & A2B high solid tumors that is in phase Ia clinical trials; PORT-7, an A2AR inhibitor to treat A2A & A2B high solid tumors that is in phase Ib clinical trials; PORT-1, an intratumoral amphiphilic solutions for treatment of advanced soft tissue sarcoma, which is in phase 3 clinical trials; PORT-4, a nanolipogel co-formulations to treat of solid tumors that is in preclinical trials; and PORT-5, a VLP-STING to treat of solid tumors that is in preclinical trials. The company is based in Tortola, British Virgin Islands. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/28 - 08/01 Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale AbbVie Stock Eyes Breakout as Pipeline and Profits Grow Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
